Get started
Work

Abstract GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-gs3-05
Authors: E. P. Mamounas, H. Bandos, K. J. Sweeney, K. M. Tran, E. Chen, P. Rastogi, V. Valero, T. J. Freeman, C. E. Geyer, L. Fehrenbacher, S. K. Chia, A. M. Brufsky, J. M. Walshe, G. S. Soori, S. R. Dakhil, S. Paik, S. M. Swain, N. Wolmark, W. F. Symmans
Institutions: AdventHealth Orlando, AdventHealth, University of Pittsburgh, The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NSABP Foundation, Kaiser Permanente, Kaiser Permanente Vallejo Medical Center, BC Cancer Agency, University of British Columbia, Magee-Womens Hospital, Cancer Trials Ireland, St. Vincent's University Hospital, Cancer Center of Kansas, Via Christi Regional Medical Center, Yonsei University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, MedStar Health, UPMC Health System
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W7129387779
Cites:
Cited by:
Related to: